We are live on ! Find out more
BIB icon

ProShares Ultra NASDAQ Biotechnology

25 hedge funds and large institutions have $7.83M invested in ProShares Ultra NASDAQ Biotechnology in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 2

110% more capital inflows, than outflows

Capital inflows: $3.38M | Capital outflows: $1.61M

47% more call options, than puts

Call options by funds: $2.14M | Put options by funds: $1.46M

32% more funds holding

Funds holding: 19 → 25 (+6)

3.29% more ownership

Funds ownership: 3.85% → 7.14% (+3.3%)

50% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 6

Holders
25
Holders Change
+6
Holders Change %
+31.58%
% of All Funds
0.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
3
Reduced
6
Closed
2
Calls
$2.14​M
Puts
$1.46​M
Net Calls
+$683​K
Net Calls Change
+$713​K

BIB Hedge Fund Activity: Q4 2022 in Review

25 of the 6,238 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q4 2022, worth a combined $7.83M — up 131% from $3.39M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new BIB positions and 2 closed out — a net gain of 5 holders — while 3 added to existing stakes and 6 trimmed.

The largest buyer was Jane Street, opening a new position worth an estimated $809K. The largest seller was Susquehanna International Group, cutting an estimated $1.5M.

  • 25 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q4 2022, up from 19 in Q3 2022.
  • Funds reported $7.83M of ProShares Ultra NASDAQ Biotechnology stock for Q4 2022, up 131% quarter-over-quarter.
  • 7 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q4 2022 and 2 closed out, a net change of +5 holders.
  • The largest ProShares Ultra NASDAQ Biotechnology buyer in Q4 2022 was Jane Street, an estimated $809K added.
  • The largest ProShares Ultra NASDAQ Biotechnology seller in Q4 2022 was Susquehanna International Group, an estimated $1.5M sold.

Based on aggregated 13F filings for Q4 2022.